Activatable Photosensitizers: From Fundamental Principles to Advanced Designs
Top Cited Papers
Open Access
- 21 February 2025
- journal article
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 64 (15) , e202423348
Abstract
Photodynamic therapy (PDT) is a promising treatment that uses light to excite photosensitizers in target tissue, producing reactive oxygen species and localized cell death. It is recognized as a minimally invasive, clinically approved cancer therapy with additional preclinical applications in arthritis, atherosclerosis, and infection control. A hallmark of ideal PDT is delivering disease‐specific cytotoxicity while sparing healthy tissue. However, conventional photosensitizers often suffer from non‐specific photoactivation, causing off‐target toxicity. Activatable photosensitizers (aPS) have emerged as more precise alternatives, offering controlled activation. Unlike traditional photosensitizers, they remain inert and photoinactive during circulation and off‐target accumulation, minimizing collateral damage. These photosensitizers are designed to “turn on” in response to disease‐specific biostimuli, enhancing therapeutic selectivity and reducing off‐target effects. This review explores the principles of aPS, including quenching mechanisms stemming from activatable fluorescent probes and applied to activatable photosensitizers (RET, PeT, ICT, ACQ, AIE), as well as pathological biostimuli (pH, enzymes, redox conditions, cellular internalization), and bioresponsive constructs enabling quenching and activation. We also provide a critical assessment of unresolved challenges in aPS development, including limitations in targeting precision, selectivity under real‐world conditions, and potential solutions to persistent issues (dual‐lock, targeting moieties, biorthogonal chemistry and artificial receptors). Additionally, it provides an in‐depth discussion of essential research design considerations needed to develop translationally relevant aPS with improved therapeutic outcomes and specificity.Keywords
Funding Information
- Terry Fox Research Institute (PPG1137)
- Canadian Institutes of Health Research (PJT190047 and 190093)
- Canada Excellence Research Chairs, Government of Canada (950-232468)
- Princess Margaret Cancer Foundation
This publication has 265 references indexed in Scilit:
- Controllable Assembly of Cu2+ and Chlorin E6 for H2S‐Activatable Recognition of Bacterial Infection and Enhanced Antibacterial TherapyAdvanced Healthcare Materials, 2024
- Overcoming ROS Resistance of Photodynamic Therapy with Self‐Assembled Nano‐Prodrugs for Efficient Triple‐Negative Breast CancerAdvanced Functional Materials, 2023
- Recent Progress in the Development of Multifunctional Nanoplatform for Precise Tumor PhototherapyAdvanced Healthcare Materials, 2020
- Photosensitizers with Aggregation‐Induced Emission: Materials and Biomedical ApplicationsAdvanced Materials, 2018
- Cancer‐Associated, Stimuli‐Driven, Turn on Theranostics for Multimodality Imaging and TherapyAdvanced Materials, 2017
- Activatable Photosensitizers: Agents for Selective Photodynamic TherapyAdvanced Functional Materials, 2016
- Targeting‐Triggered Porphysome Nanostructure Disruption for Activatable Photodynamic TherapyAdvanced Healthcare Materials, 2014
- Photodynamic Therapy With Aminolevulinic Acid Topical Solution andVisible Blue Light in the Treatment of Multiple Actinic Keratoses of the Faceand ScalpArchives of Dermatology, 2004
- Abnormal expression of hepatoma specific ?-glutamyl transferase and alteration of ?-glutamyl transferase gene methylation status in patients with hepatocellular carcinomaCancer, 2000
- Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration With VerteporfinArchives of Ophthalmology (1950), 1999